Kaleido Biosciences has patented a method using glycan therapeutics to reduce inflammation in gastrointestinal inflammatory diseases with immune imbalances. The composition includes specific branched glycans with defined characteristics. This innovation could potentially offer new treatment options for such conditions, including cancer therapy. GlobalData’s report on Kaleido Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Kaleido Biosciences, Cancer treatment biomarkers was a key innovation area identified from patents. Kaleido Biosciences's grant share as of February 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
Glycan therapeutic preparation for reducing gastrointestinal inflammation in immune imbalance
A recently granted patent (Publication Number: US11883422B2) discloses a method for reducing inflammation in gastrointestinal inflammatory diseases by administering a composition containing a glycan therapeutic preparation. The glycan therapeutic preparation includes branched glycans with specific glycan units, an average degree of branching, and a particular ratio of alpha- to beta-glycosidic bonds. This method aims to reduce inflammation in subjects with immune imbalances, potentially addressing conditions like inflammatory bowel disease, ulcerative colitis, graft versus host disease, or psoriasis.
Furthermore, the method may involve the administration of a probiotic microorganism along with the glycan therapeutic preparation. It also aims to modulate the level of short-chain fatty acids in the subject, potentially increasing the level of SCFAs like acetate, propionate, and butyrate. Additionally, the method may stimulate the growth or activity of beneficial gut bacteria, such as Bacteroidetes, Prevotella, Ruminococcus, and others. The administration of the composition could also lead to the modulation of biomarkers and cytokines, including interleukins, C-reactive protein, and tumor necrosis factor-alpha, among others. This patent provides a detailed method for addressing gastrointestinal inflammatory diseases by targeting immune imbalances and inflammation through the use of specific glycan therapeutic preparations and potential probiotic supplementation.
To know more about GlobalData’s detailed insights on Kaleido Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
